After H.C. Wainwright and Needham gave Nabriva (NASDAQ: NBRV) a Buy rating last month, the company received another Buy, this time from Northland Securities. Analyst Carl Byrnes maintained a Buy rating on Nabriva today and set a price target of $12.50. The company’s shares closed last Monday at $2.06.
Byrnes observed:
“We are forecasting peak global sales of XENLETA at $1B, supported by XENLETA’s clinical differentiation and oral/IV dosing forms.”
According to TipRanks.com, Byrnes is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -11.6% and a 28.4% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Aridis Pharmaceuticals Inc, and Adamas Pharmaceuticals.
Nabriva has an analyst consensus of Strong Buy, with a price target consensus of $8.70.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.27 and a one-year low of $1.12. Currently, Nabriva has an average volume of 1.27M.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NBRV in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
